Medivir enters into licensing agreement with Ubiquigent for preclinical program USP7
Stockholm, Sweden— Medivir AB (Nasdaq Stockholm: MVIR) announced today that it had entered into a license agreement with Ubiquigent Limited (Ubiquigent) for Medivir’s preclinical USP7 research program. Under the terms of the agreement, Medivir has granted Ubiquigent an exclusive worldwide license to develop and commercialize the program including all associated compounds across any therapeutic indication(s) in return for agreed revenue share upon successful development or commercialization by Ubiquigent. Ubiquitin specific peptidase 7 (USP7) is a deubiquitylating (DUB) enzyme that has